Recent Updates
Recently added Catalysts
RLAY Positive Sentiment

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

Wednesday, February 19, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Relay Therapeutics, a clinical-stage precision medicine company, plans to announce its fourth quarter and full year 2024 financial results on February 26, 2025. This report will come after the U.S. financial markets close, providing insights into the company's recent corporate highlights. The use of advanced computational and experimental technologies signifies Relay's ongoing commitment to transforming the drug discovery process.
Price reaction · baseline $3.92 (2025-02-18 close) · hit after-hours · 1 other RLAY headline(s) in the window, move may be shared
day 0 close · peak
+6.1%
day 1
+4.3%
day 3
-1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Relay Therapeutics is preparing to release its financial results.
  • The announcement points to transparency about corporate developments.
  • The company is engaged in the clinical-stage of drug discovery, indicating active progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025.
About Relay Therapeutics

Frequently Asked Questions

When will Relay Therapeutics report its Q4 2024 financial results?

Relay Therapeutics will report its Q4 2024 financial results on February 26, 2025.

What stock exchange is Relay Therapeutics listed on?

Relay Therapeutics is listed on Nasdaq under the ticker symbol RLAY.

What is the focus of Relay Therapeutics?

Relay Therapeutics focuses on transforming drug discovery through advanced technologies.

What type of company is Relay Therapeutics?

Relay Therapeutics is a clinical-stage precision medicine company.

ShareAdd on Google
Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics financial results Q4 2024 Nasdaq drug discovery
Last updated: Feb 19, 2025

Biotech snapshot

Cash runway
$911M liquidity · $18M/mo burn
~50 mo
Minimal dilution risk
Lead asset
RLY-8161Phase 1
Advanced NRAS-Mutant Melanoma →

Catalyst track record

+284%
best trade around RLAY's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RLAY.

See every catalyst's timing & PoA →